Sagility Reports Strong Q2 Results, Raises Margin Guidance with Buy Ratings
Sagility reported strong Q2FY27 results with revenue growth around 22.5% year-on-year and adjusted EBITDA margins reaching 26.3%, exceeding estimates. Management maintained a low double-digit organic revenue growth outlook for FY27 despite some segment weaknesses. Strategic acquisitions like CareSeed and Chirok Health are expected to enhance capabilities and support diversification. Analysts raised margin guidance and adjusted earnings estimates, valuing the stock around Rs 57-60 based on FY28 projections, and reiterated buy recommendations.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 33/100.
Outlets measured: moneycontrol, moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 23 Oct, 05:44 am. Other outlets followed.